09:29am Tuesday 17 October 2017

One disease, two mechanisms

In a nutshell:

  • Depending on the age of the patient, prostate cancer can be caused by two different mechanisms

  • The mechanism leading to prostate cancer in younger patients is triggered by androgen hormones and induces important rearrangements in the genome of the tumour

  • Understanding how prostate cancer is triggered in younger men could have widespread clinical consequences for diagnosis and treatment

While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany*, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which causes the disease at a later age. Their findings are published today in Cancer Cell, and might have important consequences for the diagnosis and treatment of prostate cancer in younger patients.

The researchers compared the genomes of 11 early-onset tumours with 7 late-onset tumours and observed marked differences at the molecular level. The genomes of early-onset prostate tumours undergo a relatively small number of changes compared to tumours that develop in older patients.

However, this small number of events leads to crucial exchanges of DNA between chromosomes, causing genes that are normally independent to become tightly linked (known as ’fusion genes‘). Many of the genes affected by these rearrangements are usually activated by androgen hormones, such as testosterone. Through these rearrangements they become connected to cancer genes, resulting in fusion genes that can be activated by androgen hormones, so that otherwise inactive genes with the potential to cause cancer are now switched on.

“Prostate cancer in young patients appears to be specifically triggered by androgens and to involve genetic alterations that distinguish this cancer from prostate tumours in older patients,” explains Jan Korbel, who led the study at EMBL. “We also measured the levels of androgen receptors in a large cohort of patients from Hamburg, and found data consistent with our initial genomic analysis.”

Younger patients with prostate cancer tend to have higher levels of androgen hormone receptors than older patients with the same disease. This could be a natural effect, because the level of these hormones decreases in men older than 50. But it supports the researchers’ conclusion that androgens might trigger the mechanism leading to prostate cancer in younger patients, and not in older ones.

Further research is needed to provide the scientific and medical community with more details, particularly regarding the medical impact of testosterone levels in men. However, in the future these findings may have widespread clinical consequences. “We hope that our findings on the cause of the disease will promote the development of new strategies to diagnose, prevent, and even individually treat this cancer, explains Thorsten Schlomm from the Martini Klinik at the University Medical Center Hamburg-Eppendorf (UKE).

* This study is a part of the International Cancer Genome Consortium (ICGC) project. In addition to EMBL, it involves the Martini-Klinik and the University Medical Centre Hamburg-Eppendorf, both in Hamburg, the German Cancer Research Center (DKFZ) in Heidelberg, and the Max-Planck Institute for Molecular Genetics in Berlin, all in Germany.

Additional resources

Read the news release distributed by the Martini-Klinik
More information on the Korbel group

Source Article

Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer – Joachim Weischenfeldt, Ph.D.et al. – Advanced online publication in Cancer Cell on 11 February, 2013 – DOI:10.1016/j.ccr.2013.01.002

Article Abstract

Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with “classical” (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in eleven tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of >10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic “androgen-type” pathomechanism in EO-PCA.

Press Contact

Isabelle Kling, Communications Officer
EMBL Heidelberg, Meyerhofstraße 1, 69117 Heidelberg, Germany

Tel: +49 6221 387-8355
E-mail: isabelle.kling@embl.de

Lena Raditsch, Head of Communications
EMBL Heidelberg, Meyerhofstraße 1, 69117 Heidelberg, Germany

Tel: +49 6221 387-8125
E-mail: lena.raditsch@embl.de

Share on:

Health news